ATE476447T1 - Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität - Google Patents

Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität

Info

Publication number
ATE476447T1
ATE476447T1 AT03739341T AT03739341T ATE476447T1 AT E476447 T1 ATE476447 T1 AT E476447T1 AT 03739341 T AT03739341 T AT 03739341T AT 03739341 T AT03739341 T AT 03739341T AT E476447 T1 ATE476447 T1 AT E476447T1
Authority
AT
Austria
Prior art keywords
wisp
modulating
compositions
methods
activity
Prior art date
Application number
AT03739341T
Other languages
English (en)
Inventor
Luc Desnoyer
Ellen Filvaroff
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE476447T1 publication Critical patent/ATE476447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03739341T 2002-06-29 2003-06-28 Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität ATE476447T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39265202P 2002-06-29 2002-06-29
US40873902P 2002-09-06 2002-09-06
PCT/US2003/020407 WO2004003158A2 (en) 2002-06-29 2003-06-28 Methods and compositions for modulating and detecting wisp activity

Publications (1)

Publication Number Publication Date
ATE476447T1 true ATE476447T1 (de) 2010-08-15

Family

ID=30003268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03739341T ATE476447T1 (de) 2002-06-29 2003-06-28 Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität

Country Status (10)

Country Link
US (1) US7456262B2 (de)
EP (1) EP1572931B1 (de)
JP (1) JP4636497B2 (de)
AT (1) ATE476447T1 (de)
AU (1) AU2003245733B2 (de)
CA (1) CA2489515C (de)
DE (1) DE60333669D1 (de)
DK (1) DK1572931T3 (de)
IL (1) IL165776A (de)
WO (1) WO2004003158A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4636497B2 (ja) 2002-06-29 2011-02-23 ジェネンテック， インコーポレイテッド Ｗｉｓｐ活性を調節し検出するための方法及び組成物
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JP2007505131A (ja) * 2003-09-11 2007-03-08 ジェネンテック・インコーポレーテッド Ｗｉｓｐアンタゴニストの使用方法
US8460658B2 (en) 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
WO2005035548A1 (en) * 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
WO2005094888A1 (ja) * 2004-03-31 2005-10-13 Two Cells Co. Ltd. 損傷組織の治療剤と治療方法
CN113087772B (zh) * 2021-04-27 2022-04-22 清华大学深圳国际研究生院 一种rhamm拮抗多肽及其衍生物与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406441T1 (de) * 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
PT1623990E (pt) * 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
JP4636497B2 (ja) 2002-06-29 2011-02-23 ジェネンテック， インコーポレイテッド Ｗｉｓｐ活性を調節し検出するための方法及び組成物
JP2007505131A (ja) 2003-09-11 2007-03-08 ジェネンテック・インコーポレーテッド Ｗｉｓｐアンタゴニストの使用方法

Also Published As

Publication number Publication date
WO2004003158A2 (en) 2004-01-08
EP1572931A4 (de) 2006-03-01
AU2003245733A1 (en) 2004-01-19
AU2003245733B2 (en) 2009-11-26
CA2489515C (en) 2013-01-22
IL165776A0 (en) 2006-01-15
IL165776A (en) 2010-06-30
US7456262B2 (en) 2008-11-25
EP1572931B1 (de) 2010-08-04
US20060073135A1 (en) 2006-04-06
WO2004003158A3 (en) 2005-08-04
JP2006516956A (ja) 2006-07-13
EP1572931A2 (de) 2005-09-14
CA2489515A1 (en) 2004-01-08
DE60333669D1 (de) 2010-09-16
DK1572931T3 (da) 2010-11-08
JP4636497B2 (ja) 2011-02-23

Similar Documents

Publication Publication Date Title
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
DE69926536D1 (de) Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
DE69833014D1 (de) Menschliche toll homologen
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2003104282A8 (en) Glycoprotein vi - fc fusion protein for treating vascular disorders
DK0686161T3 (da) Alfa-underenhed af humane beta2-integriner
DE60310385D1 (de) Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon
DE69938451D1 (de) Fas peptide und antikörper zur modulierung von apoptosis
ATE473294T1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
MX2025010859A (es) Polipéptidos de fusión dap10/dap12.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE462727T1 (de) An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
DE60333669D1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
DE69115917D1 (de) Humane gammainterferonantagonisten
NO20075825L (no) Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet
DE3684578D1 (de) Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
WO2005025603A3 (en) Methods of using wisp antagonists
DE69840233D1 (de) Verfahren zur Identifizierung von an das Chaperonin CCT bindenden Substanzen
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572931

Country of ref document: EP